<DOC>
	<DOCNO>NCT01900444</DOCNO>
	<brief_summary>The aim study document immunogenicity safety booster dose IMOJEV® administer 12 month primary dose . Primary objective : - To describe immune response Japanese Encephalitis ( JE ) ( Day 0 ) 28 day ( Day 28 ) booster dose IMOJEV® administer least 1 year primary vaccination IMOJEV® . Exploratory objective : - To test non-inferiority IMOJEV® versus previous data obtain JEC15 study ( NCT01190228 ) product term seroprotection rate 28 day booster vaccination . - To describe safety profile booster dose IMOJEV® .</brief_summary>
	<brief_title>Study Booster Dose IMOJEV® Vaccine One Year After Primary Immunization Healthy Children South Korea</brief_title>
	<detailed_description>All participant previously participate Study JEC12 ( NCT 01396512 ) prim IMOJEV® vaccine receive single booster dose IMOJEV® vaccine 12 month primary dose . They assess immune response Day 28 booster dose monitor safety Day 28 . The duration participant 's participation study approximately 6 month .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Must participate study JEC12 receive 1 dose IMOJEV® least 12 month booster vaccination Age 2 4 year day inclusion In good general health time inclusion Informed Concent Form sign date parent ( ) another legally acceptable representative ( ) Subject parent ( ) /legally acceptable representative ( ) able attend schedule visit comply study procedure . Participation time study enrollment ( 4 week precede trial vaccination ) plan participation present trial period another clinical study investigate vaccine , drug , medical device , medical procedure 4 week precede study vaccination Known suspect congenital acquire immunodeficiency , receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Chronic illness , opinion investigator , stage might interfere trial conduct completion Receipt immune globulin , blood bloodderived product past 3 month , might interfere assessment immune response Previous vaccination flavivirus disease , include JE , another vaccine , except IMOJEV® participate JEC12 Administration antiviral within 2 month precede Visit 1 4 week follow study vaccination Receipt vaccine 4 week precede trial vaccination plan receipt vaccine 4 week follow trial vaccination , except inactivate influenza vaccination , may receive least 2 week study vaccine History central nervous system disorder disease , include seizure Planned receipt JE vaccine course study History flavivirus infection ( confirm either clinically , serologically virologically ) Administration systemic corticosteroid 2 consecutive week within 4 week precede vaccination Thrombocytopenia , contraindicate vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate vaccination Febrile illness ( temperature ≥38.0°C ) moderate severe acute illness/infection 3 day vaccination well day vaccination , accord Investigator judgment . A prospective subject include study condition resolve febrile event subside In emergency set hospitalize involuntarily Identified natural adopt child Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Japanese encephalitis</keyword>
	<keyword>Japanese encephalitis chimeric virus vaccine</keyword>
	<keyword>IMOJEV®</keyword>
</DOC>